SMN1 and proximal spinal muscular atrophy: Gene therapy with AAV-SMN1 in infantile onset SMA has also had significant effects, with 10 of 12 patients reaching CHOP-INTEND scores of ≥50 and 2 of 12 ≥ 60 (20).